Hairy Cell Leukemia (HCL) is an uncommon hematologic malignancy characterized by pancytopenia and marked susceptibility to infection. The condition is named after the excess B cells which look ‘hairy’ under a microscope.
As the number of leukemia cells increases, fewer healthy white blood cells, red blood cells and platelets are produced. The symptoms include a large spleen (splenomegalia) but without an increase of lymph nodes, and general symptoms such as fever, night sweats, fatigue, weight loss. Blood exams show the decreased number of blood cells and platelets.
According to the Hairy Cell Leukemia Foundation, the cause of the disease is still unknown but risk factors may include exposure to pesticides, herbicides and petrol or diesel fuel. Although no international prognostic system for risk stratification of HCL has been developed, ESMO guidelines consider the following clinical variables to indicate an adverse prognosis: Severe cytopenias (hemoglobin [Hgb] < 10 g/dL, platelets < 100 × 10 9/L, neutrophils < 1 ×10 9/L); Lymphadenopathy; Presence of TP53 mutations and lack of somatic mutations in the IGVH genes.
The Hairy Cell Leukemia market report covers emerging drugs, current treatment practices, Hairy Cell Leukemia market share of the individual therapies, current and forecasted Hairy Cell Leukemia Market Size from 2017 to 2030 segmented by seven major markets.
The report also provides detailed current Hairy Cell Leukemia treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Hairy Cell Leukemia Market Key Facts
As per DelveInsight estimates, the total incident population of Hairy Cell Leukemia in the 7 major markets was found to be 2,364 in 2017.
According to the Hairy Cell Leukemia Foundation, the median age at diagnosis of Hairy Cell Leukemia is 58 years and the disease is four-times more common in men than in women.
As per the Cancer Research UK, around 90 out of every 100 (90%) will survive their leukaemia for 5 years or more after they are diagnosed.
According to the National Organization for Rare Disorders, HCL affects about 6,000 persons in the United States. Approximately, 600-800 new cases are diagnosed each year. Most of the affected individuals are males of 50 years of age or older.
Visit For Sample Pages:
Key Benefits of Hairy Cell Leukemia Market Report
Hairy Cell Leukemia market report provides an in-depth analysis of Hairy Cell Leukemia Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
The Hairy Cell Leukemia market report will help in developing business strategies by understanding the Hairy Cell Leukemia Market trends & developments, key players and future market competition that will shape and drive the Hairy Cell Leukemia market in the upcoming years.
The Hairy Cell Leukemia market report covers Hairy Cell Leukemia current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Hairy Cell Leukemia market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
The Hairy Cell Leukemia market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Hairy Cell Leukemia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Hairy Cell Leukemia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Hairy Cell Leukemia Epidemiology
The Hairy Cell Leukemia epidemiology section covers insights about historical and current Hairy Cell Leukemia patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The Hairy Cell Leukemia Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hairy Cell Leukemia market or expected to get launched in the market during the study period. The analysis covers Hairy Cell Leukemia market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Owing to the launch of emerging therapies in their respective line of treatment, it is expected that the emerging therapies will gradually replace the market share of currently used therapies such as purine analogs, rituximab, and interferons.
To counter current unmet needs of the market and to provide better treatment options for Hairy Cell Leukemia, several companies are working robustly on developing new therapies with a novel mechanism of action. AstraZeneca, Janssen, Pfizer, Merck, Roche are some of the key companies in the Hairy Cell Leukemia market.
Overall, the increasing incidence of the disease along with the promising emerging pipeline therapies with a new mechanism of actions will fuel the Hairy Cell Leukemia market during the forecasted period of 2018- 2030.
Table of Contents
1. Key Insights
2. Executive Summary
3. Hairy Cell Leukemia Competitive Intelligence Analysis
4. Hairy Cell Leukemia Market Overview at a Glance
5. Hairy Cell Leukemia Disease Background and Overview
6. Hairy Cell Leukemia Patient Journey
7. Hairy Cell Leukemia Epidemiology and Patient Population
8. Hairy Cell Leukemia Treatment Algorithm, Current Treatment, and Medical Practices
9. Hairy Cell Leukemia Unmet Needs
10. Key Endpoints of Hairy Cell Leukemia Treatment
11. Hairy Cell Leukemia Marketed Products
12. Hairy Cell Leukemia Emerging Therapies
13. Hairy Cell Leukemia Seven Major Market Analysis
14. Attribute Analysis
15. Hairy Cell Leukemia Market Outlook (7 major markets)
16. Hairy Cell Leukemia Access and Reimbursement Overview
17. KOL Views on the Hairy Cell Leukemia Market.
18. Hairy Cell Leukemia Market Drivers
19. Hairy Cell Leukemia Market Barriers
21. DelveInsight Capabilities
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Hairy Cell Leukemia (HCL) Epidemiology Forecast to 2030
DelveInsight’s Hairy Cell Leukemia (HCL) Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Hairy Cell Leukemia (HCL) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Hairy Cell Leukemia Pipeline Insights, 2020
Hairy Cell Leukemia Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Hairy Cell Leukemia market.
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States